Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results
CMO Bettica Outlines Development Approach
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.
